ARTICLE | Company News
Airmid, Kineta, Inc. deal
July 13, 2009 7:00 AM UTC
Kineta's Kineta One LLC subsidiary received exclusive, worldwide rights to develop and commercialize Airmid's peptide portfolio of potassium channel Kv1.3 (KCNA3) blockers. Kineta expects to conduct ...